表紙
市場調査レポート

中国の医薬品産業:多国籍&国内バイオ製薬企業・産業動向・事業環境・法規制・市場成長促進因子&阻害因子・市場機会・課題の最新分析

Pharmaceutical Industry China - Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

発行 Kelly Scientific Publications 商品コード 301001
出版日 ページ情報 英文 182 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
中国の医薬品産業:多国籍&国内バイオ製薬企業・産業動向・事業環境・法規制・市場成長促進因子&阻害因子・市場機会・課題の最新分析 Pharmaceutical Industry China - Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges
出版日: 2015年07月01日 ページ情報: 英文 182 Pages
担当者のコメント
Deirdre Kelly博士により毎年発行される、中国における医薬品産業シリーズです。中国の医薬品市場は世界で第3位になり、大手製薬会社のキーマン達への豊富なネットワークによるインタビューで得た中国参入へのニーズやその規制動向、各治療薬別市場規模、国内の医薬品企業プロファイリングなど、中国の医薬品市場への参入に向けた確かな最新の情報とデータをお届けいたします。原本見計らいも可能でございますので、お申し付けください。
概要

当レポートでは、中国の医薬品産業について調査し、中国における慢性疾患有病率統計、経済環境および事業環境、疾患区分別の主要企業、関連法規制、薬剤開発の動向、医薬品の輸出入の動向、流通販売構造、多国籍企業による取り組み、国内企業のプロファイルなどをまとめています。

第1章 サマリー

第2章 慢性疾患の有病率統計

第3章 事業環境

  • 経済指標、貿易政策、商品・商取引統計
  • 中国のGDP
  • 中国における年間医療費支出
  • 世界・中国の経済発展の経緯
  • 中国の経済発展の経緯:他の新興諸国との比較
  • 中国の経済発展の経緯:先進諸国(米国・欧州)との比較

第4章 中国の医薬品市場

  • 世界の医薬品市場の概要
  • 中国の医薬品市場の概要
  • 中国の医薬品産業における主要企業
    • 抗アレルギー薬市場
    • ぜんそく・COPD薬市場
    • 前立腺肥大症薬市場
    • 抗うつ薬市場
    • 皮膚炎薬市場
    • 糖尿病薬市場
    • 高血圧薬市場
    • 脂質異常症薬市場
    • 老年性認知症薬市場
    • 癌治療薬市場
    • 関節リウマチ薬市場
    • 眼科薬市場
    • 肝疾患薬市場
    • 抗生物質市場
    • ワクチン市場

第5章 政府・法規制環境

  • 第12次5カ年計画
  • 中国における医薬品の知的財産権
  • SFDA(国家食品薬品監督管理局)
  • 中国の医薬品流通販売プロセス
  • EDL (Essential Drug List ) に対する多国籍企業の戦略
  • ZocorによるEDLへのアクセス
  • EDLの中での多国籍企業によるベストセラー薬剤
  • EDL統合の前に健闘すべき重要戦略

第6章 中国:世界第2位の医薬品市場

  • 中国:新興市場の最前線
  • ジェネリック医薬品市場と中国
  • 新製品の開発
  • 薬剤開発のコストとアウトソーシング
  • 薬剤開発のケーススタディ:Beijing Continent Pharmaceuticals
  • 中国の医薬品輸出市場
  • スポットライト:China Medical City Taizhou

第7章 世界の医薬品企業の中国への関心

  • Abbott
  • AstraZeneca China
  • Bayer China
  • Boehringer Ingelheim China
  • Eli Lilly China
  • GlaxoSmithKline China
  • Johnson & Johnson Medical China
  • Merck China
  • Novartis China
  • Novo Nordisk China
  • Pfizer China
  • Roche China
  • Sanofi China

第8章 中国の医薬品企業

  • Amoytop Biotech
  • Beijing Continent Pharmaceuticals
  • FusoGen Pharmaceuticals
  • Shanghai Huaguan Biochip
  • SiBiono GeneTech
  • Sinovac Biotech

第9章 市場成長促進因子・阻害因子・課題・市場機会の分析

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 2015PIC

"Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challengess" provides a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 265 tables & figures within 182 pages. The Chinese biopharmaceutical market is presented as follows:

  • By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)
  • By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)

A wealth of financial information is provided including:

  • Company financials, sales & revenue figures
  • China GDP, economic growth, export (bulk drug, formulations) figures
  • Indian health expenditure as a function of GDP
  • Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
  • Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)
  • Projected figures of strategic emerging industry GDP percentage contribution

SWOT, Economic and Business Environment specifics include:

  • Key strengths, weaknesses and threats influencing leading player position within the market
  • Top Five Contract Pharmaceutical Export Markets of China
  • Major players within China's leading therapeutic markets (e.g., cancer, allergy, liver disease)
  • Multinational penetration into the Chinese Pharma Market
  • Comprehensive product portfolios, R&D activity and pipeline therapeutics
  • M&A activity and future strategies of top Chinese pharmacos
  • Economic indicators, trade policy, merchandise and commercial trade statistics
  • Gross Domestic Product of China, historic and projection analysis
  • Chinese economic outlook in comparison to advanced economies
  • Three Tier 'Pharmerging' Markets with Potential for Significant Growth
  • Prescription drug sales distribution channels in China
  • Major biogeneric products in China

This report highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.

  • Amoytop Biotech
  • Active Pharmaceutical Products
  • Beijing Continent Pharmaceuticals
  • FusoGen Pharmaceuticals
  • Shanghai Huaguan Biochip
  • SiBiono GeneTech
  • Abbott
  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson Medical
  • Merck
  • Novartis
  • Pfizer
  • Roche

Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

What you will gain:

  • An in-depth understanding of the Chinese biopharmaceutical market and it's environment
  • Current market facts, figures and product lines of key players in the industry
  • An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market
  • Knowledge of how the Chinese pharma market will integrate into the global healthcare market
  • Information on key regulatory and government policies
  • Data on levels of private and publically funded biopharma studies in China
  • Strategies on how to adapt and restructure current business models to this industry

This report tackles key concerns to the Chinese biopharmaceutical market such as:

  • Lack of regulatory policy and legislation
  • Reimbursement schemes and payers concerns
  • Funding and government sponsorship issues
  • International scepticism of Chinese safety and efficacy therapeutic profiles

This report will tell you if the companies mentioned are:

  • Strong, competitive players
  • Pooling their resources for specific growth and therapeutic areas
  • Investing strategically in R&D
  • Have a history of strategic M&A activity

Table of Contents

1 Summary

  • 1.1 Objectives of Report
  • 1.2 Scope of Study
  • 1.3 Data Sources and Methodology
  • 1.4 Key Findings and Observations
  • 1.5 Executive Summary
    • 1.5.1 Chronic Disease in China
    • 1.5.2 Chinese Pharmaceutical Market
    • 1.5.3 Government and Regulation Environment 12th Five Year Plan
    • 1.5.4 Generic Medication Market and China
    • 1.5.5 Novel Product Drug development
    • 1.5.6 Global Pharmaceutical Companies Interest in China

2 Chronic Disease Prevalence Statistics

3 Business Environment

  • 3.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics
  • 3.2 Gross Domestic Product of China Analysis
  • 3.3 Annual Health Expenditure in China Analysis
  • 3.4 Global and Chinese Economic History
  • 3.5 Chinese Economic History in Comparison to Emerging Markets and Developing Countries
  • 3.6 Chinese Economic History in Comparison to Advanced Economies (US, Europe)

4 Chinese Pharmaceutical Market

  • 4.1 Global Pharma Market Overview
  • 4.2 China Pharma Market Overview
  • 4.3 Main Players in China's Pharmaceutical Industry
    • 4.3.1 Anti-Allergy Drug Market
    • 4.3.2 Asthma/COPD Drug Market
    • 4.3.3 Benign Prostate Hyperplasia Drug Market
    • 4.3.4 Anti-Depressant Drug market
    • 4.3.5 Dermatitis Drug Market
    • 4.3.6 Diabetes Drug Market
    • 4.3.7 Hypertension Drug Market
    • 4.3.8 Dyslipidaemia Drug Market
    • 4.3.9 Senile Dementia Drug Market
    • 4.3.10 Cancer Drug Market
    • 4.3.11 Rheumatoid Arthritis Drug Market
    • 4.3.12 Ophthalmological Drug Market
    • 4.3.13 Liver Disease Drug Market
    • 4.3.14 Antibiotic Drug Market
    • 4.3.15 Vaccine Market

5 Government and Regulation Environment

  • 5.1 12th Five Year Plan
  • 5.2 Intellectual Property for Pharmaceuticals in China
  • 5.3 State Food and Drug Administration (SFDA)
  • 5.4 Pharmaceutical Distribution Process in China
  • 5.5 Multinational Company Strategy for the Essential Drug List
    • 5.5.1 Expanded Coverage of Medical Conditions
    • 5.5.2 A Standardized Essential Drug List
    • 5.5.3 Increased EDL Use in Class 3 and Class 2 Hospitals
    • 5.5.4 Increased Product Quality
  • 5.6 How did Zocor Gain Access to the National Essential Drug List?
  • 5.7 What are the Top Selling Agents from Multinational Companies on the Essential Drug List?
  • 5.8 What Key Strategies Should be Investigated Prior to Essential Drug List Integration?

6 China - Second Largest Pharma Market 2014

  • 6.1 China - At the Forefront of Emerging Markets
  • 6.2 Generic Medication Market and China
  • 6.3 Novel Product Drug Development
  • 6.4 Drug Development Cost and Outsourcing
  • 6.5 Drug Development Case Study - Beijing Continent Pharmaceuticals
  • 6.6 China's Pharmaceutical Export Market
  • 6.7 Spot Light - China Medical City Taizhou

7 Global Pharmaceutical Companies Interest in China

  • 7.1 Abbott
    • 7.1.1 AbbVie China
  • 7.2 AstraZeneca China
  • 7.3 Bayer China
  • 7.4 Boehringer Ingelheim China
  • 7.5 Eli Lilly China
  • 7.6 GlaxoSmithKline China
  • 7.7 Johnson & Johnson Medical China
  • 7.8 Merck China
  • 7.9 Novartis China
  • 7.10 Novo Nordisk China
  • 7.11 Pfizer China
    • 7.11.1 Pfizer China R&D Centre
    • 7.11.2 Pfizer China Products
    • 7.11.3 Pfizer Financials
  • 7.12 Roche China
  • 7.13 Sanofi China

8 Chinese Pharmaceutical Companies

  • 8.1 Amoytop Biotech
    • 8.1.1 Overview
    • 8.1.2 Active Pharmaceutical Products
    • 8.2.1 Research and Development
    • 8.2.2 Financial Information
  • 8.3 Beijing Continent Pharmaceuticals
  • 8.4 FusoGen Pharmaceuticals
    • 8.4.1 Financial Information
  • 8.5 Shanghai Huaguan Biochip
    • 8.5.1 Financial Information
  • 8.6 SiBiono GeneTech
    • 8.6.1 Financial Information
  • 8.7 Sinovac Biotech
    • 8.7.1 Financial Information
    • 8.7.2 New Products
    • 8.7.3 Split Virion Pandemic Influenza Vaccine
    • 8.7.4 RabEnd
    • 8.7.5 Pipeline Portfolio
    • 8.7.6 EV71 virus Vaccine
    • 8.7.7 Pneumococcal Conjugate Vaccine
    • 8.7.8 Pneumococcal Polysaccharide Vaccine
    • 8.7.9 Varicella Vaccine
    • 8.7.10 Measles, Mumps and Rubella Vaccines
    • 8.7.11 Rotavirus Vaccine

9 Drivers, Restraints, Challenges and Opportunity Analysis

  • 9.1 Key Drivers of the Pharmaceutical Market in China
  • 9.2 Key Restraints of the Pharmaceutical Market in China
  • 9.3 Challenges of the Pharmaceutical Industry in China
  • 9.4 Opportunities Within BioPharma China

List of Tables

  • Table 2.1: Most Prominent Cancer Manifestations in China
  • Table 2.2: Top Fifty Diseases in China Today (non-cancer)
  • Table 2.3: Top Infectious Disease States in China Today
  • Table 3.1: World Trade Organisation Basic Indicators on China
  • Table 3.2: World Trade Organisation Trade Policy of China
  • Table 3.3: World Trade Organisation Merchandise Trade Statistics: China
  • Table 3.4: World Trade Organisation Commercial Services Trade Statistics: China
  • Table 3.5: Summary of International Monetary Fund Members' Quota, Reserve Position, SDR Holdings, Outstanding Credit, Recent Lending Arrangements, Projected Payments Due and Monthly Historical Transactions of China
  • Table 3.6: China Statistics
  • Table 4.1: Top Global Pharma Markets 2003-2013
  • Table 4.2: Major Players in China's Anti-Allergy Drug Market
  • Table 4.3: Major Players in China's Asthma Drug Market
  • Table 4.4: Major Players in China's Benign Prostate Hyperplasia (BPH) Drug Market
  • Table 4.5: Major Players in China's Anti-Depressant Drug Market
  • Table 4.6: Prescription Dermatitis Drug Industry Sub-Markets and Associated Therapeutics
  • Table 4.7: Top Prescription Dermatitis Drugs on the Chinese Market
  • Table 4.8: Major Players in China's Dermatitis Drug Market
  • Table 4.9: Major Players in China's Diabetic Drug Market
  • Table 4.10: Major Players in China's Hypertension Drug Market
  • Table 4.11: Major Players in China's Dyslipidaemia Drug Market
  • Table 4.12: Major Players in China's Senile Dementia Drug Market
  • Table 4.13: Major Players in China's Cancer Drug Market
  • Table 4.14: Major Players in China's Rheumatoid Arthritis Drug Market
  • Table 4.15: Major Players in China's Ophthalmological Drug Market
  • Table 4.16: Major Players in China's Liver Disease Drug Market
  • Table 4.17: Major Players in China's Antibiotic Drug Market
  • Table 5.1: Seven Strategic Emerging Industries of China's 12th Five Year Plan 2011-2015
  • Table 5.2: Outline of the Chinese Promotion Plan for the Implementation of the National Intellectual Property Strategy, 2012
  • Table 5.3: Challenges facing the Pharmaceutical Distribution Business in China
  • Table 5.4: Prescription Drug Sales Distribution Channels in China
  • Table 5.5: Extra Government Guidelines for the Chinese Essential Drug System
  • Table 6.1: Major Biogeneric Products in China
  • Table 6.2: Imported Therapeutics with Administrative Protection in China
  • Table 6.3: Expired Proprietary Pharmaceuticals in China
  • Table 6.4: Reasons Why Multinational Companies Seek CMO's in China
  • Table 6.5: Comparison of Clinical Trial Cost between China and the USA
  • Table 6.6: Five Functional Districts of China Medical City
  • Table 6.7: Five Key R&D and Manufacturing Areas within China Medical City
  • Table 7.1: Top Multinational Company Performance, China
  • Table 7.2: Abbott Areas of Expertise
  • Table 7.3: Abbott Key Global Products
  • Table 7.4: AbbVie (Abbott) Speciality Care Products Holding Market-Leading Positions
  • Table 7.5: Abbott China Anaesthesia Product Profile
  • Table 7.6: Abbott China Cardiovascular Product Profile
  • Table 7.7: Abbott China Vaccine Product Profile
  • Table 7.8: Abbott China Digestion Product Profile
  • Table 7.9: Abbott China HIV Product Profile
  • Table 7.10: Abbott Rheumatology HIV Product Profile
  • Table 7.11 Abbott China Gynaecological Product Profile
  • Table 7.12 Abbott China Urological Product Profile
  • Table 7.13 Abbott China Liver Disease Product Profile
  • Table 7.14 Abbott China Diagnostic Product Profile
  • Table 7.15: Abbott China Molecular Diagnostic Product Profile
  • Table 7.16: Abbott Blood Glucose Meter Product Profile
  • Table 7.17: Abbott Cardiovascular Product Profile
  • Table 7.18: Abbott Rapid Bedside Diagnostic/ Point of Care Product Profile
  • Table 7.19: Important Milestones in AstraZeneca China's History
  • Table 7.20: AstraZeneca China Anaesthetic Range of Products
  • Table 7.21: AstraZeneca China Cardiovascular and Metabolism Range of Products
  • Table 7.22: AstraZeneca China Gastrointestinal Range of Products
  • Table 7.23: AstraZeneca China Infection Range of Products
  • Table 7.24: AstraZeneca China Neurology Range of Products
  • Table 7.25: AstraZeneca China Oncology Range of Products
  • Table 7.26: AstraZeneca China Respiratory Range of Products
  • Table 7.27: AstraZeneca Top Branded Pharmaceuticals Globally 2014
  • Table 7.28: AstraZeneca Sales (US$ Mil) of Top Branded Pharmaceuticals Globally 2010-2014
  • Table 7.29: Bayer China Important Milestones
  • Table 7.30: Therapeutic Areas Covered by Bayer Healthcare Pharmaceuticals in China
  • Table 7.31: Bayer - Leading Therapeutics in China
  • Table 7.32: Bayer Top Selling Consumer Health Products
  • Table 7.33: Bayer Key Product Patent Expiration Dates China
  • Table 7.34: Boehringer Ingelheim Major Products in China
  • Table 7.35: Main Therapeutic Areas of Interest to Boehringer Ingelheim China
  • Table 7.36: Global Therapeutic Pipeline, Boehringer Ingelheim
  • Table 7.37: Major Global Boehringer Ingelheim Therapeutic Products
  • Table 7.38: Lilly Late Stage New Molecular Entities: Indication, Geography & Developments
  • Table 7.39: Lilly New Molecular Entities Approved, Under Regulatory Review & in Clinical Trials in the US, Japan and Europe
  • Table 7.40: Lilly Key Product by US Revenue and Patent Protection Data FY2014
  • Table 7.41: Lilly Key Product by Non-US Revenue and Patent Protection Data FY2014
  • Table 7.42: Eli Lilly Top Selling Global Branded Pharmaceuticals 2012-2013 & Percentage Change
  • Table 7.43: Lilly Top Selling Global Branded Pharmaceuticals FY2014 ($ millions) Within and Outside the US Market
  • Table 7.44: GlaxoSmithKline Prescription Portfolio and Indications in China
  • Table 7.45: GlaxoSmithKline Vaccine Portfolio and Indications in China
  • Table 7.46: GlaxoSmithKline Over the Counter Portfolio and Indications in China
  • Table 7.47: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, FY2012-2014
  • Table 7.48: GlaxoSmithKline Global Vaccine Sales FY2012-2013
  • Table 7.49: Significant Milestones in Johnson and Johnson China History
  • Table 7.50: Johnson & Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area and Percentage Change, 2012-2014
  • Table 7.51: Merck Serono Pharmaceutical Key Therapeutic Areas in China
  • Table 7.52: Merck Serono Fertility and Infertility Therapeutic Portfolio in China
  • Table 7.53: Merck Serono Therapeutic Portfolio in China
  • Table 7.54: Merck Pharmaceutical Hong Kong Therapeutic Portfolio
  • Table 7.55: Merck Main Pharmaceutical Brand Sales Figures FY2012-FY2014
  • Table 7.56: Merck Global Pharmaceutical, Animal Health and Consumer Health Sales 2012-2013
  • Table 7.57: Merck Top Ten Global Pharmaceutical Brand Sales 2012-2013
  • Table 7.58: Range of Diabetic Products from Novo Nordisk China
  • Table 7.59: QUICKFACTs - Pfizer China
  • Table 7.60: Important Milestones - Pfizer China
  • Table 7.61: Pfizer Range of Infectious Disease Therapeutics for Chinese Health Care Market
  • Table 7.62: Pfizer Range of Mental Health Products for Chinese Health Care Market
  • Table 7.63: Pfizer Range of Genitourinary Products for Chinese Health Care Market
  • Table 7.64: Pfizer Range of Endocrine Products for Chinese Health Care Market
  • Table 7.65: Pfizer Range of Women's Health Products for Chinese Health Care Market
  • Table 7.66: Pfizer Range of Cardiovascular Disease Products for Chinese Health Care Market
  • Table 7.67: Pfizer China - Range of Oncology Products for Chinese Health Care Market
  • Table 7.68: Pfizer Key Consumer Healthcare Global Products
  • Table 7.69: Pfizer Key Speciality Care Global Products
  • Table 7.70: Pfizer Key Oncology Global Products
  • Table 7.71: Pfizer Key Global Established Products
  • Table 7.72: Pfizer Key Innovative Products in Emerging Markets
  • Table 7.73: Pfizer Key Animal Health Global Products
  • Table 7.74: Pfizer Product Sales with Significant Impact on Revenues 2013:2014 Comparison
  • Table 7.75: Roche Pharmaceuticals Product List in China
  • Table 7.76: Roche Global Sales (CHF Millions) by Therapeutic Area, 2012-2014 and Percentage Change (CER)
  • Table 7.77: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, 2011-2014 and Percentage Change (CER)
  • Table 7.78: Seven Growth Platforms of Sanofi China
  • Table 7.79: Key Therapeutic Areas of Sanofi China
  • Table 8.1: Important Milestones in Amoytop Biotech's Development
  • Table 8.2: Amoytop Biotech Main Objectives of Research and Development Division
  • Table 8.3: Amoytop Biotech Panel of Recombinant Protein Therapeutics in Clinical Studies
  • Table 8.4: Amoytop Biotech Portfolio of Patented Y-Shaped Branched Pegylated Recombinant Protein Therapeutics within Clinical Investigation in China
  • Table 8.5: Current Recombinant protein therapeutics by Amoytop Biotech
  • Table 8.6: Active Pharmaceutical Product Portfolio of Amoytop Biotech
  • Table 8.7: Milestones Achieved by FusoGen Pharmaceuticals
  • Table 8.8: Research and Development Sub-groups of FusoGen Pharmaceuticals
  • Table 8.9: Shanghai Huaguan Biochip Rapid Test Portfolio
  • Table 8.10: Shanghai Huaguan Biochip Multi Drugs of Abuse Test Profile
  • Table 8.11: Shanghai Huaguan Biochip Infectious Disease Test Portfolio
  • Table 8.12: Shanghai Huaguan Biochip Diagnostic Test Portfolio
  • Table 8.13: Shanghai Huaguan Biochip Laboratory Service Portfolio
  • Table 8.14: Intracellular Functions of the Gene Therapy Agent, Gendicine by SiBiono GeneTech
  • Table 8.15: Gendicine - Potential Oncology Indications for Future Approval
  • Table 8.16: Current Human Vaccine Portfolio of Sinovac Biotech
  • Table 8.17: Important Milestones in the History of Sinovac Biotech
  • Table 8.18: Pipeline Portfolio of Sinovac Biotech
  • Table 8.19: Total Sales Figures Sinovac Biotech 2007-2012
  • Table 9.1: Key Drivers of the Pharmaceutical Market in China
  • Table 9.2: Key Restraints of the Pharmaceutical Market in China
  • Table 9.3: Key Challenges of the Pharmaceutical Market in China
  • Table 9.4: Patent Expirations of Selected Top Brand Name Therapeutics by 2020
  • Table 9.5: Leading Pharmaceutical Areas with Significant Opportunities in China

List of Figures

  • Figure 2.1: Proportional (%) Mortality Rate of Total Deaths in China, All Ages
  • Figure 3.1: China GDP Figures 2006-2015
  • Figure 3.2: Annual Health Expenditure in China 2006-2015
  • Figure 3.3: Global, Emerging Market & Developing Countries Economic Growth Change 2010-2013
  • Figure 3.4: Global, Emerging Market & Developing Countries & China Economic Growth Change 2010-2013
  • Figure 3.5: Global, Emerging Market & Developing Countries & Russia Economic Growth Change 2010-2013
  • Figure 3.6: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010-2013
  • Figure 3.7: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013
  • Figure 3.8: Global, US and Germany Economic Growth 2010-2013
  • Figure 3.9: US and UK Gross Domestic Product per capita Forecast 2010-2017
  • Figure 3.10: Global, France and Italy Economic Growth 2010-2013
  • Figure 3.11: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017
  • Figure 3.12: Global, UK and Spain Economic Growth 2010-2013
  • Figure 3.13: Global, Japan and Canada Economic Growth 2010-2013
  • Figure 3.14: China, Brazil and India Gross Domestic Product per capita Forecast 2010-2017
  • Figure 4.1: The Chinese Healthcare Industry by Sector
  • Figure 4.2: Global Diabetes Market, USA, Europe, Japan, RoW, 2015
  • Figure 4.3: Diabetes Market China 2009-2015
  • Figure 4.4: Global Dementia Market 2011-2017
  • Figure 4.5: Market Share of State-Owned, Privately-Owned and Foreign-Owned Enterprises in the Chinese Vaccine Market
  • Figure 5.1: Projected Figures of Strategic Emerging Industry GDP Percentage Contribution to 2020
  • Figure 5.2: State Drug and Food Administration, China, Application and Approval Procedure for Imported Drugs
  • Figure 5.3: State Drug and Food Administration, China, Application and Approval Procedure for Clinical Trials
  • Figure 5.4: Revenue Share (Percentage) of Major Players in Chinese Pharmaceutical Distribution Market
  • Figure 5.5: Revenue Share (Billion $) of Major Players in Chinese Pharmaceutical Distribution Market
  • Figure 5.6: Number of Drugs on Essential Drug List by Western Therapeutic and Traditional Chinese Medicine, 2009-2014
  • Figure 5.7: Sales of Merck's Zocor and its Performance After Inclusion on Essential Drug List
  • Figure 6.1: Three Tier 'Pharmerging' Markets with Potential for Significant Growth
  • Figure 6.2: Number of Investigational New Drug Applications in China 2003-2013
  • Figure 6.3: Number of New Drug Applications in China 2003-2013
  • Figure 6.4: Current Number of Novel Therapeutics in Phase I, Phase II and Phase III Clinical Trials in China
  • Figure 6.5: Percentage of Clinical Trial Drug by Disease State
  • Figure 6.6: China's Regional Pharmaceutical Processing Trade Export Market Share Percentage
  • Figure 6.7: Contract Amount of China's Regional Pharmaceutical Processing Trade Export
  • Figure 6.8: Top Five Contract Pharmaceutical Export Markets of China
  • Figure 7.1: Abbott Division Sales Percentage by Diagnostics, Nutrition, Medical Devices & Established Pharmaceuticals 2014
  • Figure 7.2: Abbott Medical Device Segment Sales 2014 - Vascular, Diabetes and Vision
  • Figure 7.3: Abbott Laboratories Geographic Distribution of Revenue -USA, Established and Emerging Markets
  • Figure 7.4: Abbott Laboratories Established and Emerging Revenue Share (%) 2012-2015
  • Figure 7.5: Abbott - Business Specialization Strategy: Diversified Medical Products and Research-Based Pharmaceuticals
  • Figure 7.6: Abbott Diversified Medical Product Portfolio
  • Figure 7.7: AbbVie Global Revenue 2013-2014
  • Figure 7.8: AbbVie Global, International and USA Total Revenue 2014
  • Figure 7.9: AbbVie Global, USA & International Revenue Generated 2013-2014
  • Figure 7.10: AbbVie Revenue Generated by Creon, DuoDopa and Synthroid 2013-2014
  • Figure 7.11: AstraZeneca Sales Revenue (US$ Millions) in China, FY2010-2014
  • Figure 7.12: AstraZeneca Global Revenue (Billions) by Geographic Area: USA, Europe, China, Japan, Canada, FY2014
  • Figure 7.13: AstraZeneca Cardiovascular Product (Atacand, Crestor, Seloken/Toprol-XL) Global Sales FY2010-2014
  • Figure 7.14: AstraZeneca Gastrointestinal Product (Nexium) Global Sales FY2010-2014
  • Figure 7.15: AstraZeneca Infection Product (Synagis) Global Sales FY2010-2014
  • Figure 7.16: AstraZeneca Neuroscience Product (Seroquel-IR, Seroquel-XR) Global Sales FY2010-2014
  • Figure 7.17: AstraZeneca Oncology Product (Zoladex) Global Sales FY2010-2014
  • Figure 7.18: AstraZeneca Respiratory/Inflammation Product (Pulmicort, Symbicort) Global Sales 2010-2012
  • Figure 7.19: Bayer Geographical Sales China, USA, Germany FY2013-2014
  • Figure 7.20: Bayer Sales Distribution by Division: Healthcare, Crop Science, Material Science FY2014
  • Figure 7.21: Bayer Healthcare Sales Breakdown: Pharmaceuticals and Consumer Health FY2014
  • Figure 7.22: Boehringer Ingelheim Global Sales by Geographic Region, Europe, Americas, Asia, Australia, Africa FY2014
  • Figure 7.23: Boehringer Ingelheim Sales by Product Class FY2014
  • Figure 7.24: Boehringer Ingelheim Oncology Compounds in Development
  • Figure 7.25: Lilly Global Revenue FY2010-FY2014
  • Figure 7.26: GlaxoSmithKline Total Sales, Pharmaceutical, Vaccine and Consumer Healthcare Sales 2012-2014 (£ Billions)
  • Figure 7.27: GlaxoSmithKline Global Pharmaceutical Sales (£ Millions) by Therapeutic Area, FY2012-2013
  • Figure 7.28: GlaxoSmithKline Sales by Therapeutic Area FY2014
  • Figure 7.29: GlaxoSmithKline Global Vaccine Sales, FY2012-2014
  • Figure 7.30: GlaxoSmithKline Global Sales by Geographic Region - USA, Europe, Emerging Markets, Japan, FY2012-2014
  • Figure 7.31: Johnson & Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area, 2012-2014
  • Figure 7.32: Novartis International Sales (%) by Geographic Region, FY2013-FY2014
  • Figure 7.33: Novartis International Sales (US$ Millions) by Geographic Region, FY2012-FY2014
  • Figure 7.34: Novo Nordisk Total China Sales FY2009-FY2014
  • Figure 7.35: Novo Nordsk Total Diabetes Care Market Sales Performance (DKK Millions) China FY2010-FY2014
  • Figure 7.36: Novo Nordisk Diabetes Care (NovoRapid/NovoLog, NovoMix/NovoLog Mix, Levemir, Modern Insulin, Human Insulin, Victoza) Sales Performance (DKK Millions) China FY2010-FY2014
  • Figure 7.37: Business Sectors - Pfizer China
  • Figure 7.38: Roche Total Global Sales (CHF Millions) FY2012-FY2014
  • Figure 7.39: Roche Global Sales (CHF Billions) by Therapeutic Area, FY2012-FY2014
  • Figure 7.40: Roche Pharmaceutical Division Emerging Market Total Sales FY2011-FY2014
  • Figure 7.41: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, FY2012 - FY2014
  • Figure 7.42: Roche Pharmaceutical Division Sales in China FY2012-FY2014
  • Figure 7.43: Sanofi Geographic Market Share - Emerging Markets, USA and Western Europe FY2013-FY2014
  • Figure 7.44: Sanofi Geographic Market Share (%) -China, Russia and USA 2012
  • Figure 7.45: Sanofi Global Diabetes Revenue by Brand FY2014
  • Figure 7.46: Sanofi Global Rare Disease Revenue by Brand FY2014
  • Figure 7.47: Sanofi Global Multiple Sclerosis Revenue by Brand FY2014
  • Figure 7.48: Sanofi Global Oncology Revenue by Brand FY2014
  • Figure 8.1: FusoGen Pharmaceuticals Product Pipeline and Clinical Trial Progression
  • Figure 8.2: Shanghai Huaguan Biochip Serial Analysis of Gene Expression (SAGE) Service
  • Figure 8.3: Total Sales Figures Sinovac Biotech 2007-2012
  • Figure 8.4: Percentage of Sales Attributed to Healive Vaccine, 2009-2012
  • Figure 8.5: Reported Sales of Healive Vaccine, 2009-2012
  • Figure 8.6: Reported Sales of Bilive Vaccine, 2009-2012
  • Figure 8.7: Reported Sales of Anflu Vaccine, 2009-2012
  • Figure 8.8: Reported Sales of Panflu Vaccine, 2009-2011
Back to Top